# ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

> **NCT00661076** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 10 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** adefovir dipivoxil
- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT00661076
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661076, "ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00661076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*